Literature DB >> 33573250

Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.

Dylan M Johnson1,2, Beatrice Cubitt3, Tia L Pfeffer2,4, Juan Carlos de la Torre3, Igor S Lukashevich2,4.   

Abstract

Defective interfering particles (DIPs) are naturally occurring products during virus replication in infected cells. DIPs contain defective viral genomes (DVGs) and interfere with replication and propagation of their corresponding standard viral genomes by competing for viral and cellular resources, as well as promoting innate immune antiviral responses. Consequently, for many different viruses, including mammarenaviruses, DIPs play key roles in the outcome of infection. Due to their ability to broadly interfere with viral replication, DIPs are attractive tools for the development of a new generation of biologics to target genetically diverse and rapidly evolving viruses. Here, we provide evidence that in cells infected with the Lassa fever (LF) vaccine candidate ML29, a reassortant that carries the nucleoprotein (NP) and glycoprotein (GP) dominant antigens of the pathogenic Lassa virus (LASV) together with the L polymerase and Z matrix protein of the non-pathogenic genetically related Mopeia virus (MOPV), L-derived truncated RNA species are readily detected following infection at low multiplicity of infection (MOI) or in persistently-infected cells originally infected at high MOI. In the present study, we show that expression of green fluorescent protein (GFP) driven by a tri-segmented form of the mammarenavirus lymphocytic choriomeningitis virus (r3LCMV-GFP/GFP) was strongly inhibited in ML29-persistently infected cells, and that the magnitude of GFP suppression was dependent on the passage history of the ML29-persistently infected cells. In addition, we found that DIP-enriched ML29 was highly attenuated in immunocompetent CBA/J mice and in Hartley guinea pigs. Likewise, STAT-1-/- mice, a validated small animal model for human LF associated hearing loss sequelae, infected with DIP-enriched ML29 did not exhibit any hearing abnormalities throughout the observation period (62 days).

Entities:  

Keywords:  LASV vaccine development; Lassa virus (LASV); defective interfering particles; homologous and heterologous interference; molecular virology of mammalian arenaviruses; safety in small animal models

Year:  2021        PMID: 33573250      PMCID: PMC7912207          DOI: 10.3390/v13020214

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  62 in total

1.  A novel role for viral-defective interfering particles in enhancing dendritic cell maturation.

Authors:  Jacob S Yount; Thomas A Kraus; Curt M Horvath; Thomas M Moran; Carolina B López
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

2.  Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.

Authors:  Marco A Goicochea; Juan C Zapata; Joseph Bryant; Harry Davis; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2012-01-09       Impact factor: 3.641

3.  Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest.

Authors:  Sebastien F Emonet; Lucile Garidou; Dorian B McGavern; Juan C de la Torre
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-10       Impact factor: 11.205

4.  Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment.

Authors:  Y Riviere; R Ahmed; P J Southern; M J Buchmeier; M B Oldstone
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

Review 5.  Lassa virus diversity and feasibility for universal prophylactic vaccine.

Authors:  Igor S Lukashevich; Slobodan Paessler; Juan Carlos de la Torre
Journal:  F1000Res       Date:  2019-01-31

6.  Lassa fever outbreak continues across Nigeria.

Authors:  Sanjeet Bagcchi
Journal:  Lancet Infect Dis       Date:  2020-05       Impact factor: 25.071

7.  Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans.

Authors:  Yan Sun; Deepika Jain; Cynthia J Koziol-White; Emmanuelle Genoyer; Micah Gilbert; Karla Tapia; Reynold A Panettieri; Richard L Hodinka; Carolina B López
Journal:  PLoS Pathog       Date:  2015-09-03       Impact factor: 6.823

8.  In vivo ligands of MDA5 and RIG-I in measles virus-infected cells.

Authors:  Simon Runge; Konstantin M J Sparrer; Charlotte Lässig; Katharina Hembach; Alina Baum; Adolfo García-Sastre; Johannes Söding; Karl-Klaus Conzelmann; Karl-Peter Hopfner
Journal:  PLoS Pathog       Date:  2014-04-17       Impact factor: 6.823

9.  The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.

Authors:  David Safronetz; Kyle Rosenke; Jonna B Westover; Cynthia Martellaro; Atsushi Okumura; Yousuke Furuta; Joan Geisbert; Greg Saturday; Takashi Komeno; Thomas W Geisbert; Heinz Feldmann; Brian B Gowen
Journal:  Sci Rep       Date:  2015-10-12       Impact factor: 4.379

Review 10.  Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.

Authors:  Francis Ifedayo Ibukun
Journal:  Viruses       Date:  2020-03-31       Impact factor: 5.048

View more
  4 in total

Review 1.  A Virus Is a Community: Diversity within Negative-Sense RNA Virus Populations.

Authors:  Lavinia J González Aparicio; Carolina B López; Sébastien A Felt
Journal:  Microbiol Mol Biol Rev       Date:  2022-06-23       Impact factor: 13.044

Review 2.  The evolution of cheating in viruses.

Authors:  Asher Leeks; Stuart A West; Melanie Ghoul
Journal:  Nat Commun       Date:  2021-11-26       Impact factor: 14.919

Review 3.  Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments.

Authors:  Hannah L Murphy; Hinh Ly
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 4.  Lassa fever - the road ahead.

Authors:  Robert F Garry
Journal:  Nat Rev Microbiol       Date:  2022-09-12       Impact factor: 78.297

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.